Calcium flux in the podocytes is critical for normal and pathophysiological regulation of this type 26 of cells, and excessive calcium signaling results in podocytes damage and improper glomeruli 27 function. Purinergic activation of P2 receptors is a powerful and rapid signaling process; 28 however, the exact physiological identity of P2 receptors subtypes in podocytes remains 29 essentially unknown. The goal of this study was to determine P2 receptors profile in podocytes 30 of the intact Sprague Dawley rat glomeruli using available pharmacological tools. Glomeruli 31 were isolated by differential sieving, loaded with Fluo-4/Fura Red cell permeable calcium 32 indicators and purinergic response in the podocytes was analyzed with ratiometric confocal 33 fluorescence measurements. Various P2 receptors activators were tested and compared to the 34 effect of ATP; specifically, UDP, MRS 2768, MRS 2365 MRS 4062, and MRS 2768 were analyzed. Antagonists (MRS 2500, 5-BDBD, A438079 and 36 NF449) were tested when 10 μM ATP was applied as the EC 50 for ATP activation of the calcium 37 influx in the podocytes was determined to be 10.7 ± 1.5 μM. Several agonists including MRS 38 2365 and 2-meSADP caused calcium flux. Importantly, only P2Y 1 specific antagonist MRS 39 2500 (1 nM) precluded the effects of ATP concentrations of the physiological range. 40
INTRODUCTION 50
Nowadays there has been shown a role for ATP in various key physiological processes, such as 51 embryonic development, cell differentiation, apoptosis, sensation, cell signaling etc. There is 52 growing evidence that changes in ATP signaling contribute to a plethora of physiological and 53 pathophysiological processes in the kidney; therefore, disturbances in purinergic signaling can 54 lead to impaired renal and cardiovascular function (48) . 55
In the kidney, purinergic P2 receptors are expressed at both the apical and basolateral 56 membranes of renal tubular cells, in the renal vasculature, glomerular mesangial cells and 57 podocytes (1, 2, 57, 58) . For example, in the immunohistochemical study by Turner et al (57) 58 P2X 1 , P2X 2 and P2Y 1 receptors were found in the smooth muscle layer of the intrarenal vessels; 59 P2Y 1 was also found on mesangial cells, the brush border membrane of the proximal straight 60 tubule and on peritubular fibroblasts. In the kidney cortex, P2Y 4 receptors were found on the 61 tubule epithelium of the proximal convoluted tubule. A number of ex vivo and in vivo evidence 62 revealed a functional role for the P2Y 2 receptors in the collecting duct (29, 35, 46, 50, 54, 60, 63 65). P2X 4 and P2X 6 receptors were identified throughout the renal tubule epithelium from the 64 proximal tubule to the collecting duct. P2X 5 receptors were found to be expressed on medullary 65 collecting duct cells and the apical membrane of the S3 segment of the proximal tubule. 66
As for the glomeruli, there have been few studies investigating the pattern of the P2 67 receptors in the different cell types comprising the glomerulus, probably because of the complex 68 structure of this nephron segment, which includes endothelial and mesangial cells encapsulated 69 by visceral (podocytes) and parietal epithelial cells (2, 40) . Earlier studies performed in cultured 70 cells report the mRNA expression of the P2Y 2 , P2Y 4 and P2Y 6 in mesangial cells (18, 22, 61) , 71 and P2Y 2 in the endothelium of the glomerulus (3, 42). Other RT-PCR studies have detected 72 the mRNAs of the P2Y 1 , P2Y 2 , P2Y 6 , and P2X 7 receptors within glomeruli, although it was 73 hypothesized that extracellular nucleotides modulate podocyte function mainly by an activation 74 of both P2Y 2 and P2Y 6 receptors rather than P2Y 1 (12). However, a later paper published by 75
Hohenstein et al revealed that P2Y 1 deficiency protects from renal disease progression and 76 capillary rarefaction during the passive crescentic glomerulonephritis (21). The authors have 77 detected the P2Y 1 mRNA in extracts of mouse cortical kidney tissue, laser-microdissected 78 glomeruli, and tubulointerstitium as well as in cultured (undifferentiated) podocytes and 79 mesangial cells (21) . 80
Members of the P2X receptors subfamily were shown to be expressed in rat glomerular 81 mesangial cells (18). P2X 1 receptors have been localized to the vascular smooth muscle of 82 intrarenal arteries, including arcuate and interlobular arteries, and afferent arterioles, but not 83 glomeruli, postglomerular efferent arterioles, and renal tubules (5). It has been recently 84 demonstrated that P2X 7 receptor-mediated Nlrp3-inflammasome activation is a genetic 85 determinant of macrophage-dependent crescentic glomerulonephritis (7); moreover, P2X 7 86 deficiency has been shown to be renoprotective in mice compared to wild-type controls, 87 evidenced by a reduction in proteinuria and decreased glomerular injury (56). Importantly, 88 electron microscopy, immunostaining and mRNA have shown low-level P2X 7 receptor 89 expression in the glomeruli under normal conditions, which is significantly up-regulated (mainly 90 in podocytes) in diabetic and hypertensive rat models, and therefore can be associated with the 91 pathogenesis of glomerular cell injury (62). 92
Podocytes are highly specialized differentiated cells that are important regulators of the 93 glomerular filtration barrier; these cells contain a plethora of receptors for different hormones 94 and auto/paracrine factors, activation of which can affect glomerular filtration (11, 17, 43, 52 Wilmington, MA) were used. Rats were provided with food and water ad libitum. 120 121 Glomeruli isolation. Glomeruli isolation protocol was described previously (23). Briefly, 122 the rat kidneys were removed, and the cortex was isolated and minced using a singled edge 123 razor blade. The minced tissue was sequentially pushed through stainless steel dissociation 124 sieves of 100 and then 140 mesh (04-881-5Z and 04-881-5X; Thermo Fisher) using the culture 125
with Mayers Hematoxylin (DAKO), dehydrated and mounted with permanent mounting media 141 (SAKURA). 142
143
Confocal laser-scanning fluorescence microscopy. Calcium imaging was performed with 144 laser scanning confocal microscope system Nikon A1-R. Images were collected in time series 145 (xyt, 8s per frame) with the Nikon imaging software. Changes in intracellular Ca 2+ concentration 146
were estimated according to a protocol described previously (44) from ratiometric fluorescence 147 images of Fluo-4 (excitation at 488 nm, emission at 520 ± 20 nm) and Fura Red (excitation at 148 488 nm, emission at >600 nm) loaded glomeruli. Emitted light was collected by the objective 149 lens Plan Apo ×60 oil DIC2. All experiments were performed with the same instrument settings 150 (laser power, offset, gain on both detector channels). The glomeruli suspension was loaded 1C) was measured for the point of the maximal intracellular calcium concentration increase. 209
The EC 50 value was calculated according to the Hill's equation and was determined equal to 210 10.7 ± 1.5 μM. 211
To test the implication of the metabotropic P2Y receptors into the purinergic signaling in 212 the podocytes, we probed the ATP response in the calcium-free solution containing a divalent 213 ions chelator (0.2 mM EGTA). Figure 2A shows a typical fast transient evoked by 10 µM ATP in 214 the podocytes in the calcium-free solution (time of decay 20.02 ± 2.44 s). As may be inferred 215 from the graph, the time of decay is significantly faster (see Fig. 2B ) than in calcium-containing 216 solution, whereas the magnitude of the response is even greater in the calcium-free bath 217 solution ( Fig. 2C ). However, from the comparison of the values of the integral intracellular 218 calcium release represented by the AUC in Fig. 2D it is clear that the total calcium release in the 219 calcium-free is smaller than in the calcium-containing solution, which can be explained by 220 activation of P2X component of intracellular calcium transient. 221
222
Pharmacological effect of the P2 receptors agonists on the intracellular calcium 223 activation in the podocytes. Table 1 
provides information about P2X and P2Y receptors 224
agonists and antagonists used in the current study. Among various P2 receptors' activators 225 tested here, MRS 2768, MRS 4062 and UDP, which activate P2Y 2 , P2Y 4 /P2Y 2 /P2Y 6 and 226 P2Y 6 /P2Y 14 , respectively, did not affect intracellular calcium concentration of the podocytes 227 when applied in both low and high concentrations (see Fig. 3 ); as a control 10 to 50 µM of ATP 228 was added at the end of each experiment in order to ensure that the podocytes are still 229 responsive ( Fig. 3) . α,β-Methylene and bzATP, which are established compounds known to 230 activate most of P2X receptors and P2X 7 /P2X 1 /P2Y 1 , respectively, only slightly elevated the 231 intracellular calcium concentration ( Fig. 4 ). Therefore, it can be hypothesized that P2X 232 component only represents a minor purinergic receptors component responsible for the calcium 233 flux in the podocytes under normal conditions. 234
Based on this hypothesis and available specific antagonists, the next stage of the study 235 was focused on the P2Y receptors as the most promising candidates for the transduction of the 236 purinergic signaling. One of the well-known potent purinergic agonists displaying selectivity for 237 From these observations, one can conjecture that P2Y receptors, especially P2Y 1 and 244 probably P2Y 12 are involved into the regulation of the calcium flux in the podocytes. To further 245 probe this hypothesis with the available pharmacological activators, we have tested the effects 246 of a highly potent, selective P2Y 1 receptor agonist MRS 2365 (6, 49) on the glomeruli 247 preparation which displays no activity at P2Y 12 receptors and only very low agonist activity at 248 P2Y 13 . 5 µM of MRS 2365 was applied in the calcium-free solution and induced a fast transient 249 with a magnitude of 2.59 ± 0.5 fold; interestingly, following application of 10 µM ATP did not 250 cause any elevations of the calcium concentration ( Fig. 6A ). 10 µM ATP and even higher 251 concentration of MRS 2365 (20 µM) were also applied vice versa and no response to MRS 2365 252 was recorded in this case ( Fig. 6B ). Therefore, it can be concluded that amongst P2Y receptors 253 were incubated with all the antagonists for 10 min before the ratiometric measurements were 261 started. 262
As seen from Fig. 7A , 5-BDBD, which is known to specifically inhibit P2X 4 receptors 263 subtype, modulated the time of decay, however did not significantly alter the maximum of the 264 increase induced by ATP. This was confirmed with the use of NF 449 (specific for 265 P2X 1 /P2X 2 /P2X 1/5 /P2X 2/3/ P2X 3 /P2X 4 ) and A438079 (specific for P2X 7 ), which in a similar way 266 affected the parameters of the ATP-evoked transient, but did not block the response (Figs. 7B 267 and 7C, respectively). Hereof we can conclude that high doses of the P2X blockers known to 268 date can non-specifically modulate the kinetics of the purinergic response in podocytes, prolong 269 Ca 2+ transient and slightly moderate the integral calcium release. These data indicate that P2X 270 receptors 1 to 4 and P2X 7 are most likely not involved into the transduction of the purinergic 271 signaling in the rat podocytes under normal conditions. However, in general, the putative P2X 272 component cannot be excluded, especially in the disease states. 273
As a result of the described pharmacological screening, P2Y 1 remained as a main target 274 for the ATP signal. To probe this hypothesis, we have utilized a novel selective antagonist of 275 the P2Y 1 receptors MRS 2500. Incubation with MRS 2500 (in concentrations any more than 276 1 nM for 10 min) precluded the development of the calcium transient evoked by 10 µM ATP (see 277 As seen from Fig. 9B , application of the P2 receptors' antagonists allowed localizing 294 several members of the P2X subfamily that do not participate in the purinergic signal 295 transduction in the podocytes, these being P2X 1 /P2X 1/5 /P2X 2/3 /P2X 3 / P2X 2 /P2X 4 (proved with the 296 application of NF449). The absence of the P2X 4 and P2X 7 receptors' effect in the studied 297 pathway was also confirmed with 5-BDBD and A438079, respectively. Interestingly, among the 298 activators and inhibitors applied in this study the most potent proved to be ones targeting P2Y 1 . 299
This leaves the G-protein coupled P2Y 1 receptor as the most likely pharmacologically selected 300 P2 family member to be responsible for the purinergic signaling and consequent calcium flux in 301 the podocytes; the contribution of P2Y12 and P2Y13 receptors can be excluded due to the 302 results of the use of MRS 2500. Figure 10 shows the immunohistochemical staining for P2Y 1 303 receptors (APR-009 antibody, Alomone Labs) in the Sprague Dawley rat kidney and lung. As 304 can be seen from the representative images ( Fig. 10B ), P2Y 1 receptor is highly expressed in the 305 podocytes of glomeruli. We also performed staining in isolated glomeruli to avoid background 306 signals from the tubules surrounding glomeruli (Fig. 10C ). Negative (Fig. 10A) In the recent years, several new classes of purinergic modulators, which are highly 331 specific for certain P2Y or P2X subfamily members, have been discovered. However, most of 332 the purinergic modulators are concentration-dependent specific and high concentrations of the 333 drugs can target several homologous receptors. One of the best examples of such effect is a 334 popular P2X 7 activator BzATP, which can also activate both P2X 1 and P2Y 1 receptors in 335 concentrations above 10 µM (see Table 1 ). Here we have implicated various cutting-edge 336 pharmacological tools in order to identify the receptor that would mediate ATP-induced calcium 337 increase in the podocytes of the normotensive rat glomeruli. As has been noted in several 338 reviews relevant to the regulation of the renal function by purinergic signaling, specific 339
antagonists are very much needed to better characterize the functional role of the P2 receptors 340 (48, 53, 59). In current study we have applied the most specific recently developed 341 pharmacological tools, as well as the classic compounds that have been long used in the field of 342 the purinergic signaling, in order to differentiate between the P2 signals in the glomerulus. As 343 summarized in Fig. 9 , pharmacological screening allowed us to discriminate between the P2X 344 and P2Y mediated calcium release and to show the major role of the P2Y 1 . Our observations 345 based on the effects of various agonists with the partially overlapping target receptors allow 346 concluding that P2Y 2 , P2Y 4 , P2Y 6 and P2Y 14 are most likely not involved into the transduction of 347 the ATP-induced signaling in the podocytes. In contrast to some of the previously published 348 data (2), we found no evidence of P2Y 2 receptor involvement into the ATP signal transduction in 349 the podocytes. However, Bailey et al recognize that further studies using a more sensitive 350 direct technique will be necessary to establish definitely whether P2Y 1 receptors are expressed 351 in the glomeruli (2). 352
Our results reveal that apart from P2Y 1 , P2Y 12 and P2Y 13 could be involved into the The P2X component of the purinergic signaling in the podocytes has been speculated 359 upon in the previous decade. Most studies showed low expression profiles of the P2X receptors 360 in the glomeruli, which are however increased under pathological conditions. For example, 361 P2X 7 receptor expression in the glomeruli is significantly enhanced in the diabetic and 362 hypertensive rats (62). Generally, P2X 7 receptors mediate apoptotic, necrotic and 'aponecrotic' 363 cell death (16, 55), so this could be important in the disease states associated with proteinuria 364 and podocytes death. In accordance with these observations, our data show that there is a 365 P2X 7 -mediated component in the calcium release stimulated by ATP, which is however quite 366 small compared to the P2Y -mediated release. We have not detected any significant P2X 367 receptors activity in the podocytes of the rat glomeruli under normal conditions; application of 368 the P2X receptors antagonists revealed that neither of the P2X receptors 1 to 4 nor 7 is involved 369 into the signal transduction. However, it cannot be excluded that P2X receptors could mediate 370 ATP-dependent calcium changes in the pathological conditions. Our experiments revealed that 371 upon inhibition of the P2Y 1 component with MRS 2500 the response to high concentration of 372 ATP (100 µM) is sustained, this allowing us to suggest a putative role of the P2X receptors in 373 the disease states accompanied with abnormally high ATP production. 374
Interestingly, in our experiments, total [Ca 2+ ] i release is always higher in the outer 375 solution containing 2 mM Ca 2+ . In the 2 mM Ca 2+ solution the response is longer and total 376 calcium release is increased. However, the peak value of the ATP-induced response is higher 377 in zero extracellular calcium, which could be potentially mediated by the gap junction channel 378 coupling. However, we believe that this mechanism is not involved in these effects, as the 379 response in 0 mM Ca 2+ would not involve calcium entry through the channels from the 380 extracellular side. Higher peak in zero Ca 2+ that we consistently observed can be potentially 381 associated with more efficient depot storage capacity in the presence of low calcium. 382
It should be noticed that in general there is a significantly less calcium release in the 383 absence of the extracellular calcium, whereas in the 2 mM Ca 2+ solution we observed a longer 384 ("slow") component of the transient, which could have been assigned to the P2X signaling. As 385 we have tested the P2X component responsible for the calcium release and concluded that the 386 P2X component cannot be excluded, the longer calcium release could be explained by the 387 activity of the P2X receptors. However, taking into consideration that tested P2X 7 inhibitors did 388 not alter the magnitude of the response to 10 µM ATP ( Fig. 9B) It is well-known that multiple G protein-coupled receptors (GPCR) have been implicated 397 in the pathogenesis of glomerular disease processes. P2Y 1 receptors identified here are 398 coupled to G q activated cascades (41, 63). Activation of P2Y 1 receptors could be a strong 399 regulator of podocyte function and signaling and through the G q mediated intracellular cascades 400 would trigger the second intracellular messengers and could further lead to activation of 401 calcineurin or calmodulin -dependent mechanisms (39, 63). G i coupled receptors of the P2Y 402 family P2Y 12 and P2Y 13 are known to inhibit adenylyl cyclase and to reduce the intracellular 403 levels of cAMP. Moreover, it has been recently shown that G i proteins can activate members of 404 the Src family of tyrosine kinases (33). However, our experiments could not show any clear 405 presence of these G i coupled P2Y 12 and P2Y 13 in the podocytes, and thus G i -signaling could 406 be excluded from the signal transduction pathway, although this purinergic mechanism is quite 407 important for other physiological processes, like platelet aggregation. 408
It has been reported that the release of reactive oxygen species (ROS) leads to 409 proteinuria by affecting glomerular endothelial and epithelial cells and disturbing normal 410 glomerular permselectivity (4, 24). Importantly, it was demonstrated that NADH/NADPH 411 oxidase system that represents the main source for ROS generation in the podocytes, is 412 activated by the P2 receptors-mediated pathway (15, 45). Therefore, activation of P2 receptors 413 may finally restore cell energy homeostasis in different pathophysiological conditions preceding 414 the depression of intracellular ATP (e.g., oxidative stress, ischemia, inflammation, diabetes). 415
Moreover, recent evidence indicates that diabetic milieu, represented mainly by high glucose 416
concentration, may lead to diabetic podocytopathy -abnormalities in podocytes numbers and 417 structure or function; glucose transport activity in podocytes may be modulated by P1 and P2 418 receptors under this pathological condition (26).
Nevertheless, targeting the specific P2 419 receptors may be a means of treatment of various renal diseases associated with podocytes 420 injury. Over-induced purinergic signaling may prove detrimental in this regard and specific 421 inhibition of the P2 receptors could be of useful means to modulate the disease state. Of much 422
interest is the involvement of the P2 receptors into the pathophysiology and developments of 423 renal diseases such as glomerulonephritis.
However, there is an emerging need for the 424 development of the ligands that would not degrade in vivo to explore this in the prospective of 
